MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease
Abstract
The purpose of our study was to identify microRNAs (miRNAs) as early detectable peripheral biomarkers in Alzheimer's disease (AD). To achieve our objective, we assessed miRNAs in serum samples from AD patients and Mild cognitive impairment (MCI) subjects relative to healthy controls. We used Affymetrix microarray analysis and validated differentially expressed miRNAs using qRT-PCR. We further validated miRNA data using AD postmortem brains, amyloid precursor protein transgenic mice and AD cell lines. We identified a gradual upregulation of four miRNAs: miR-455-3p, miR-4668-5p, miR-3613-3p and miR-4674. A fifth miRNA, mir-6722, was down-regulated in persons with AD and mild cognitive impairment compared with controls. Validation analysis by qRT-PCR showed significant upregulation of only miR-455-3p (P = 0.007) and miR-4668-5p (P = 0.016) in AD patients compared with healthy controls. Furthermore, qRT-PCR analysis of the AD postmortem brains with different Braak stages also showed upregulation of miR-455-3p (P = 0.016). However, receiver operating characteristic curves (ROC) curve analysis revealed a significant area under curve (AUC) value only for miR-455-3p in the serum (AUROC = 0.79; P = 0.015) and brains (AUROC = 0.86; P = 0.016) of AD patients. Expression analysis of amyloid precursor protein transgenic mice also revealed high level of mmu-miR-455-3p (P = 0.004) in the cerebral cortex (AD-affected) region of brain and low in the non-affected area, i.e. cerebellum. Further…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miR-455-3p levels have been reported in brain tissue, CSF, plasma, fibroblasts, and lymphocytes from AD patients.
“Among these species, miR-455-3p has emerged as a promising cross-tissue biomarker candidate; levels have been reported in brain tissue, CSF, plasma, fibroblasts, and lymphocytes from AD patients, and experimental studies suggest neuroprotective effects on synaptic and mitochondrial function (Islam et al., 2024; Kumar et al., 2017; Kumar et al., 2021; Swingler et al., 2022).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Kumar et al., 2017
Cites
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462 · see citing works
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942 · see citing works
Circular RNA (circRNA) in Alzheimer’s disease (AD)
Lukiw, W. J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00307 · Cited by 636 · cited 2× · see citing works
“Alzheimer’s disease (AD) is progressive neurological disorder affecting aged humans (1).”
BackgroundCirculating miRNAs as Potential Biomarkers in Alzheimer's Disease
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M. G., Arighi, A., Fumagalli, G., & Scarpini, E. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140756 · Cited by 222 · see citing works
Adlakha, Y. K., & Saini, N. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-33 · Cited by 213 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78 · see citing works
Kumar, S., Morton, H., Sawant, N., Orlov, E., Bunquin, L. E., Pradeepkiran, J. A., Alvir, R., & Reddy, P. H. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102182 · Cited by 75 · see citing works
Self-citationSegaran, R. C., Chan, L. Y., Wang, H., Sethi, G., & Tang, F. R. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200121122910 · Cited by 42 · see citing works
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39 · see citing works
Rethinking Alzheimer’s: Novel miRNAs Illuminate a Disease Beyond the Brain
Novotný, J., Čarná, M., Dammer, E., Mao, Z., & Stokin, G. (2025) · doi:10.1101/2025.11.27.690929 · Cited by 1 · see citing works
Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease
Donepudi, K., Eadha, S., Rodarte, D., Sharma, B., & Kumar, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103211
Self-citation
- Authors
- Kumar, S., Vijayan, M., & Reddy, P. H.
- Affiliations
- Biomarker Unit, Garrison Institute on Aging
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-17
- Volume
- 26
- Issue
- 19
- Pages
- 3808-3822
- ISSN
- 0964-6906
- 1460-2083
- Cited by
- 157
- References
- 5
- Language
- en
- Funders
- National Institute of Health (AG042178, AG47812)
- Garrison Family Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review